PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease

Alcoholic liver disease (ALD) causes significant morbidity and mortality, and pharmacological treatment options are limited. In this study, we evaluated the PCSK9 inhibitor alirocumab, a monoclonal antibody that robustly reduces low-density lipoprotein cholesterol (LDL-C), for the treatment of ALD u...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ji Soo, Mukhopadhyay, Partha, Matyas, Csaba, Trojnar, Eszter, Paloczi, Janos, Yang, Yuan Ru, Blank, Brandon A., Savage, Cody, Sorokin, Alexander V., Mehta, Nehal N., Vendruscolo, Janaina C. M., Koob, George F., Vendruscolo, Leandro F., Pacher, Pal, Lohoff, Falk W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868240/
https://www.ncbi.nlm.nih.gov/pubmed/31748600
http://dx.doi.org/10.1038/s41598-019-53603-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868240/
https://www.ncbi.nlm.nih.gov/pubmed/31748600
http://dx.doi.org/10.1038/s41598-019-53603-6

Ejemplares similares